Horizon Pharma plc established this website to provide Depomed, Inc. shareholders with as much information as possible, in one location, about what we consider to be our compelling 60 percent premium proposal to combine our two companies through an all-stock, tax free transaction of $33.00 per share.*
Despite all the benefits that we, and many other Depomed shareholders who we have spoken with, believe will result from a combination of our two companies, Depomed’s board and management have been unwilling to meaningfully engage with us. It is our firm conviction that the Depomed board’s dismissive responses to our acquisition proposals prove that they are entrenched and out of step with the desires of most current shareholders.
You, the true owners of Depomed, play a more important role than ever in bringing our two companies together so that the merits of a combination are realized. We urge you to read these materials carefully. Thank you for your attention to this important matter.